Clinical trial
A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets
NCT05610189 is registered in ClinicalTrials.gov with Cerevel Therapeutics, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets
- Lead sponsor
- Cerevel Therapeutics, LLC
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 15, 2022
- Completion date
- December 17, 2023
- Enrollment
- 25 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.